TRPM4 silencing was reported to promote GSK-3β-dependent degradation of β-catenin and reduce β-catenin/Tcf/Lef-dependent transcription to inhibit cervical cancer (Armisen et al., 2011). Here, GSK3B is linked to cervical carcinoma.